Stockscreener 앱 받기
0.004
25.00%
0.0008
시간 외 거래:
.01
0.006
+150.00%
Nls Pharmaceutics Ag 주식(NLSPW)의 최신 뉴스
Pre-market Movers: STSS, THRD, PTN, VRAX... - RTTNews
Press Release Distribution & PR Platform - ACCESS Newswire
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com
NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks
Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - marketscreener.com
Kadimastem Ltd. announced that it expects to receive ILS 2 million in funding. - marketscreener.com
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider.com
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK
NLS Pharmaceutics CEO Issues Letter to Shareholders - Yahoo Finance
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com India
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - accessnewswire.com
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
AEX-2 increases total wake duration in mouse model - BioWorld Online
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Pre-IND meeting guides path forward for ITOL-102 for type 1 diabetes - BioWorld Online
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - Yahoo Finance
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - Marketscreener.com
NLS and Kadimastem to merge, aim for diabetes care innovation - Investing.com
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire
Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga
NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga India
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga
0.39%
3.66%
자본화:
|
볼륨(24시간):